Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals Plc on January 19, 2012. The filing relates to the Company's Registration Statement on Form S-3 (File No. 333-179080) and associated prospectus supplements dated January 19, 2012.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural filing regarding legal opinions and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing serves to provide copies of legal opinions from A&L Goodbody, Dublin, Ireland, concerning the legality of the Company's ordinary shares (nominal value $0.0001 per share) to be offered and sold.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, or outlook. It does not disclose specific risks or contingencies beyond the standard legal opinions regarding the share offering.
Key Facts for Investor Verification
- The filing confirms the submission of legal opinions (Exhibits 5.1 and 5.2) from A&L Goodbody regarding the validity of the share offering.
- The offering is pursuant to Registration Statement on Form S-3 (File No. 333-179080).
- The report was signed by Bruce C. Cozadd, Chairman and Chief Executive Officer, on January 18, 2012.
- Investors should review the full Form S-3 and prospectus supplements for details on the offering terms and financial data.